Infliximab, etanercept and adalimumab can induce remission and prevent both clinical and radiological disease progression in rheumatoid arthritis with significant improvement in patients' symptoms ...

The cost per ACR50/70 response ratio favored the labeled dose of etanercept compared with both the low (3 mg/kg every 8 weeks) and high (10 mg/kg every 4 weeks) maintenance doses of infliximab.

Index cases were 44 patients whose infliximab doses had been increased. Controls were patients treated with infliximab without dose increase (n = 44), and patients treated with etanercept (n = 36).

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

Erelzi (etanercept-szzs) has been approved in all ... The FDA has already approved Pfizer's Inflectra (infliximab-dyyb) and Sandoz's Zarzio (filgrastim-sndz), which are near copies of J&J's ...

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a ...

We investigated whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses to a single dose of a SARS-CoV-2 vaccine. Design Antibody responses and ...

There is a simple discount patient access scheme for spesolimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...